Brokers Offer Predictions for MREO Q1 Earnings

Mereo BioPharma Group plc (NASDAQ:MREO) – Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of Mereo BioPharma Group in a research report issued on Wednesday, March 26th. Leerink Partnrs analyst J. Schwartz anticipates that the company will post earnings per share of $0.07 for the quarter. The consensus estimate for Mereo BioPharma Group’s current full-year earnings is ($0.03) per share. Leerink Partnrs also issued estimates for Mereo BioPharma Group’s Q2 2025 earnings at $0.05 EPS, Q3 2025 earnings at ($0.02) EPS, Q4 2025 earnings at ($0.02) EPS, FY2025 earnings at $0.08 EPS and FY2026 earnings at ($0.03) EPS.

Other equities analysts have also issued reports about the company. Jefferies Financial Group initiated coverage on Mereo BioPharma Group in a research note on Friday, December 6th. They issued a “buy” rating and a $7.00 target price for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $7.00 price target on shares of Mereo BioPharma Group in a research report on Tuesday, March 18th. Lifesci Capital began coverage on shares of Mereo BioPharma Group in a research note on Tuesday, December 24th. They set an “outperform” rating and a $10.00 price objective for the company. JPMorgan Chase & Co. initiated coverage on shares of Mereo BioPharma Group in a research note on Thursday. They issued an “overweight” rating and a $7.00 target price on the stock. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $7.00 price target on shares of Mereo BioPharma Group in a research report on Wednesday, March 26th. Six investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $7.71.

Mereo BioPharma Group Stock Down 4.6 %

MREO opened at $2.30 on Monday. The business’s fifty day simple moving average is $2.72 and its 200 day simple moving average is $3.48. Mereo BioPharma Group has a 52 week low of $2.22 and a 52 week high of $5.02. The firm has a market cap of $356.84 million, a P/E ratio of -38.33 and a beta of 1.03.

Mereo BioPharma Group (NASDAQ:MREO) last issued its quarterly earnings data on Wednesday, March 26th. The company reported ($0.01) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.03).

Institutional Trading of Mereo BioPharma Group

A number of hedge funds have recently made changes to their positions in MREO. State Street Corp acquired a new stake in Mereo BioPharma Group in the third quarter valued at $195,000. Janus Henderson Group PLC lifted its position in shares of Mereo BioPharma Group by 56.7% during the third quarter. Janus Henderson Group PLC now owns 12,345,866 shares of the company’s stock worth $50,865,000 after purchasing an additional 4,464,984 shares during the last quarter. Frazier Life Sciences Management L.P. grew its stake in Mereo BioPharma Group by 15.8% in the third quarter. Frazier Life Sciences Management L.P. now owns 5,097,779 shares of the company’s stock worth $20,952,000 after purchasing an additional 696,408 shares in the last quarter. PFG Investments LLC increased its holdings in Mereo BioPharma Group by 132.0% in the fourth quarter. PFG Investments LLC now owns 39,433 shares of the company’s stock valued at $138,000 after buying an additional 22,433 shares during the last quarter. Finally, Sheets Smith Investment Management acquired a new stake in Mereo BioPharma Group during the fourth quarter valued at approximately $59,000. Institutional investors and hedge funds own 62.83% of the company’s stock.

About Mereo BioPharma Group

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.